<p>根據其最近向美國證券交易委員會提交的 13F 表格，World Investment Advisors 在第四季度將其在 CVS Health Corporation（紐約證券交易所代碼：CVS - 免費報告）的持股增加了 36.5%。該基金在此期間購買了 19,623 股後，持有 73,409 股該藥房運營商的股票。World Investment Advisors 在 CVS Health 的持股在最近一個季度末價值為 5,826,000 美元。</p>
<ul>
<li>3 只醫療保健股票將受益於這項重大法案</li>
</ul>
<p>其他幾家機構投資者也買賣了 CVS 的股票。凱通國際資產管理有限公司在第三季度將其在 CVS Health 的持倉提高了 407.2%。凱通國際資產管理有限公司目前持有 350 股該藥房運營商的股票，價值 26,000 美元，此前在上個季度又購買了 281 股。Ares Financial Consulting LLC 在第四季度購買了 CVS Health 的新頭寸，價值 29,000 美元。Dogwood Wealth Management LLC 在第四季度將其在 CVS Health 的持倉提高了 93.7%。Dogwood Wealth Management LLC 目前持有 370 股該藥房運營商的股票，價值 29,000 美元，此前在上個季度又購買了 179 股。GoalVest Advisory LLC 在第四季度購買了 CVS Health 的新頭寸，價值 32,000 美元。最後，Financial Consulate Inc.在第四季度將其在 CVS Health 的持倉提高了 99.6%。Financial Consulate Inc.目前持有 499 股該藥房運營商的股票，價值 40,000 美元，此前在上個季度又購買了 249 股。機構投資者持有該公司 80.66% 的股票。</p>
<h2>CVS Health 價格表現</h2>
<p>CVS 股票在週四開盤價為 98.14 美元。該股票的 50 日移動平均價格為 78.07 美元，200 日移動平均價格為 78.36 美元。CVS Health Corporation 的 52 周低點為 58.35 美元，52 周高點為 98.22 美元。該公司的債務與股本比率為 0.78，速動比率為 0.66，流動比率為 0.87。該公司的市值為 1,252.2 億美元，市盈率為 43.24，市盈增長比率為 0.93，貝塔值為 0.60。</p>
<ul>
<li>這隻 ETF 證明醫療保健復甦是真實的</li>
</ul>
<p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）最後一次公佈季度財報是在 5 月 6 日，星期三。該藥房運營商報告季度每股收益為 2.57 美元，超出市場共識預期的 2.21 美元，超出幅度為 0.36 美元。CVS Health 的股本回報率為 11.88%，淨利潤率為 0.72%。該公司季度收入為 1,004.3 億美元，而市場共識預期為 949.9 億美元。在去年同期，該公司每股收益為 2.25 美元。CVS Health 的季度收入同比增長 6.2%。CVS Health 已將其 2026 財年的每股收益指引設定為 7.300-7.500。作為一個整體，賣方分析師預測 CVS Health Corporation 在當前年度將發佈每股收益為 7.46。</p>
<h2>CVS Health 股息公告</h2>
<p>該公司最近還披露了季度股息，該股息於 5 月 4 日，星期一支付。4 月 23 日登記的投資者獲得每股 0.665 美元的股息。除息日期為 4 月 23 日，星期四。這相當於年化股息為 2.66 美元，收益率為 2.7%。CVS Health 的股息支付比率（DPR）目前為 117.18%。</p>
<h2>分析師評級變動</h2>
<ul>
<li>隨着收入增長，CVS Health 股價上漲，股息保持強勁</li>
</ul>
<p>幾位股票分析師對 CVS 股票發表了評論。Weiss Ratings 在 5 月 8 日，星期五的研究報告中重申了對 CVS Health 股票的 “持有（c）” 評級。Leerink Partners 在 3 月 5 日，星期四的研究報告中重申了 “跑贏大盤” 評級，並對 CVS Health 股票設定了 98.00 美元的目標價。DA Davidson 在 5 月 7 日，星期四的研究報告中將 CVS Health 股票的目標價從 80.00 美元提高至 100.00 美元，並給予該公司 “買入” 評級。巴克萊在 5 月 7 日，星期四的研究報告中將 CVS Health 股票的目標價從 93.00 美元提高至 101.00 美元，並給予該公司 “增持” 評級。最後，高盛集團在 2 月 12 日，星期四的研究報告中將 CVS Health 股票的目標價從 95.00 美元提高至 97.00 美元，並給予該股票 “買入” 評級。22 位研究分析師對該股票給予了買入評級，4 位分析師對該股票給予了持有評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 97.00 美元。</p>
<p><strong>查看我們關於 CVS 的最新報告</strong></p>
<h2>影響 CVS Health 的關鍵頭條新聞</h2>
<p>以下是本週影響 CVS Health 的關鍵新聞故事：</p>
<ul>
<li>積極情緒：摩根大通將 CVS Health 的目標股價從 101 美元上調至 111 美元，並維持超配評級，而桑福德·C·伯恩斯坦將目標從 94 美元上調至 106 美元，並維持跑贏大盤，顯示出分析師的持續信心。文章標題</li>
<li>積極情緒：CVS Health 因強勁的第一季度業績和改善的盈利能力而受到關注，最近的報道指出，該股票在超出盈利和收入預期後達到了新的 52 周高點。文章標題</li>
<li>積極情緒：分析師和市場評論也指出 CVS 是排名靠前的增長/分紅股票，這可能有助於提升對該股票的情緒。文章標題</li>
<li>中性情緒：CVS 的 Omnicare 子公司獲得破產法庭批准，將其業務出售給 GenieRx，這一步驟應有助於 CVS 繼續重塑該部門，儘管這更多是一個重組故事，而不是直接的盈利驅動因素。文章標題</li>
<li>中性情緒：CVS 還宣佈了與人工智能和 MinuteClinic 相關的舉措，包括企業人工智能的認可和減肥項目的更新，這些支持了公司的創新敍事，但不太可能成為立即的股票催化劑。文章標題</li>
<li>消極情緒：在最新一批中沒有出現重大新的消極頭條；然而，投資者可能仍在關注重組、處方變更和更廣泛的醫療保健利潤壓力的執行風險。</li>
</ul>
<h2>內部人士下注</h2>
<p>在其他 CVS Health 新聞中，執行副總裁 Tilak Mandadi 於 5 月 8 日星期五出售了 69,551 股公司的股票。股票以平均價格 89.58 美元出售，總價值為 6,230,378.58 美元。出售完成後，該執行副總裁直接持有 10,133 股公司股票，價值 907,714.14 美元。此次交易使其持股減少了 87.28%。該交易已在證券交易委員會的備案中披露，相關文件可通過此鏈接獲取。內部人士持有 0.85% 的股票。</p>
<h2>CVS Health 公司簡介</h2>
<p>（免費報告）</p>
<p>CVS Health Corporation 是一家多元化的醫療保健公司，運營着一個大型零售藥房網絡、藥房福利管理服務和醫療解決方案。公司總部位於羅德島州的伍恩索克特，追溯到 20 世紀 60 年代初，已發展成為處方藥、非處方產品、臨牀服務和健康保險產品的綜合提供商。其運營模式結合了零售藥房和店內診所與更廣泛的藥房和健康計劃能力。</p>
<p>主要業務活動包括 CVS 藥房零售業務、MinuteClinic 步入式醫療診所和提供擴展臨牀服務的 HealthHUB 地點。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過 CVS Health</li>
<li>Oklo 股票可能準備再次大幅上漲</li>
<li>D-Wave 的財報看起來疲弱，但投資者可能忽視了這一點</li>
<li>隨着人工智能反饋循環的加劇，Nebius 的上行空間擴大</li>
<li>內部交易：Okta 和 Abbott 看到買入，Micron 內部人士出售</li>
</ul>
<p><strong>想看看其他對 CVS 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com，獲取 CVS Health Corporation（NYSE:CVS - 免費報告）的最新 13F 備案和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 CVS Health 嗎？</h2>
<p>在考慮 CVS Health 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 CVS Health 並不在名單上。</p>
<p>雖然 CVS Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

西維斯

<p>世界投資顧問在第四季度將其在 CVS Health Corporation 的持股增加了 36.5%，目前持有 73,409 股，價值 583 萬美元。其他機構投資者也提高了他們的持股比例，其中 Caitong International 和 Dogwood Wealth Management 的增幅尤為顯著。CVS Health 的股票開盤價為 98.14 美元，市值為 1252.2 億美元，市盈率為 43.24。該公司報告的季度每股收益為 2.57 美元，超出預期，並宣佈每股派息 0.665 美元。分析師維持 “適度買入” 的共識評級，平均目標價為 97.00 美元</p>

<p>World Investment Advisors increased its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 36.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 73,409 shares of the pharmacy operator's stock after purchasing an additional 19,623 shares during the period. World Investment Advisors' holdings in CVS Health were worth $5,826,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根據其最近向美國證券交易委員會提交的 13F 表格，World Investment Advisors 在第四季度將其在 CVS Health Corporation（紐約證券交易所代碼：CVS - 免費報告）的持股增加了 36.5%。該基金在此期間購買了 19,623 股後，持有 73,409 股該藥房運營商的股票。World Investment Advisors 在 CVS Health 的持股在最近一個季度末價值為 5,826,000 美元。</p>
</div><ul>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只醫療保健股票將受益於這項重大法案</li>
</ul>
</div><p>Several other institutional investors have also bought and sold shares of CVS. Caitong International Asset Management Co. Ltd lifted its position in CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after purchasing an additional 281 shares during the last quarter. Ares Financial Consulting LLC bought a new position in CVS Health during the fourth quarter valued at $29,000. Dogwood Wealth Management LLC lifted its position in CVS Health by 93.7% during the fourth quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator's stock valued at $29,000 after purchasing an additional 179 shares during the last quarter. GoalVest Advisory LLC bought a new position in CVS Health during the fourth quarter valued at $32,000. Finally, Financial Consulate Inc. lifted its position in CVS Health by 99.6% during the fourth quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator's stock valued at $40,000 after purchasing an additional 249 shares during the last quarter. Institutional investors own 80.66% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者也買賣了 CVS 的股票。凱通國際資產管理有限公司在第三季度將其在 CVS Health 的持倉提高了 407.2%。凱通國際資產管理有限公司目前持有 350 股該藥房運營商的股票，價值 26,000 美元，此前在上個季度又購買了 281 股。Ares Financial Consulting LLC 在第四季度購買了 CVS Health 的新頭寸，價值 29,000 美元。Dogwood Wealth Management LLC 在第四季度將其在 CVS Health 的持倉提高了 93.7%。Dogwood Wealth Management LLC 目前持有 370 股該藥房運營商的股票，價值 29,000 美元，此前在上個季度又購買了 179 股。GoalVest Advisory LLC 在第四季度購買了 CVS Health 的新頭寸，價值 32,000 美元。最後，Financial Consulate Inc.在第四季度將其在 CVS Health 的持倉提高了 99.6%。Financial Consulate Inc.目前持有 499 股該藥房運營商的股票，價值 40,000 美元，此前在上個季度又購買了 249 股。機構投資者持有該公司 80.66% 的股票。</p>
</div><h2>CVS Health Price Performance</h2>
<div class="lb-trans"><h2>CVS Health 價格表現</h2>
</div><p>Shares of CVS stock opened at $98.14 on Thursday. The stock has a 50 day moving average price of $78.07 and a 200 day moving average price of $78.36. CVS Health Corporation has a 52-week low of $58.35 and a 52-week high of $98.22. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a market capitalization of $125.22 billion, a P/E ratio of 43.24, a P/E/G ratio of 0.93 and a beta of 0.60.</p>
<div class="lb-trans"><p>CVS 股票在週四開盤價為 98.14 美元。該股票的 50 日移動平均價格為 78.07 美元，200 日移動平均價格為 78.36 美元。CVS Health Corporation 的 52 周低點為 58.35 美元，52 周高點為 98.22 美元。該公司的債務與股本比率為 0.78，速動比率為 0.66，流動比率為 0.87。該公司的市值為 1,252.2 億美元，市盈率為 43.24，市盈增長比率為 0.93，貝塔值為 0.60。</p>
</div><ul>
<li>This ETF Is Proof That the Healthcare Rebound Is Real</li>
</ul>
<div class="lb-trans"><ul>
<li>這隻 ETF 證明醫療保健復甦是真實的</li>
</ul>
</div><p>CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the prior year, the company posted $2.25 EPS. CVS Health's quarterly revenue was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 7.46 earnings per share for the current year.</p>
<div class="lb-trans"><p>CVS Health（紐約證券交易所代碼：CVS - 獲取免費報告）最後一次公佈季度財報是在 5 月 6 日，星期三。該藥房運營商報告季度每股收益為 2.57 美元，超出市場共識預期的 2.21 美元，超出幅度為 0.36 美元。CVS Health 的股本回報率為 11.88%，淨利潤率為 0.72%。該公司季度收入為 1,004.3 億美元，而市場共識預期為 949.9 億美元。在去年同期，該公司每股收益為 2.25 美元。CVS Health 的季度收入同比增長 6.2%。CVS Health 已將其 2026 財年的每股收益指引設定為 7.300-7.500。作為一個整體，賣方分析師預測 CVS Health Corporation 在當前年度將發佈每股收益為 7.46。</p>
</div><h2>CVS Health Dividend Announcement</h2>
<div class="lb-trans"><h2>CVS Health 股息公告</h2>
</div><p>The business also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were issued a dividend of $0.665 per share. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. CVS Health's dividend payout ratio (DPR) is presently 117.18%.</p>
<div class="lb-trans"><p>該公司最近還披露了季度股息，該股息於 5 月 4 日，星期一支付。4 月 23 日登記的投資者獲得每股 0.665 美元的股息。除息日期為 4 月 23 日，星期四。這相當於年化股息為 2.66 美元，收益率為 2.7%。CVS Health 的股息支付比率（DPR）目前為 117.18%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li>
</ul>
<div class="lb-trans"><ul>
<li>隨着收入增長，CVS Health 股價上漲，股息保持強勁</li>
</ul>
</div><p>Several equities analysts have commented on CVS shares. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of CVS Health in a research report on Friday, May 8th. Leerink Partners restated an &#34;outperform&#34; rating and issued a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. DA Davidson boosted their price objective on shares of CVS Health from $80.00 to $100.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, May 7th. Barclays increased their target price on shares of CVS Health from $93.00 to $101.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, May 7th. Finally, The Goldman Sachs Group lifted their price target on shares of CVS Health from $95.00 to $97.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, February 12th. Twenty-two research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $97.00.</p>
<div class="lb-trans"><p>幾位股票分析師對 CVS 股票發表了評論。Weiss Ratings 在 5 月 8 日，星期五的研究報告中重申了對 CVS Health 股票的 “持有（c）” 評級。Leerink Partners 在 3 月 5 日，星期四的研究報告中重申了 “跑贏大盤” 評級，並對 CVS Health 股票設定了 98.00 美元的目標價。DA Davidson 在 5 月 7 日，星期四的研究報告中將 CVS Health 股票的目標價從 80.00 美元提高至 100.00 美元，並給予該公司 “買入” 評級。巴克萊在 5 月 7 日，星期四的研究報告中將 CVS Health 股票的目標價從 93.00 美元提高至 101.00 美元，並給予該公司 “增持” 評級。最後，高盛集團在 2 月 12 日，星期四的研究報告中將 CVS Health 股票的目標價從 95.00 美元提高至 97.00 美元，並給予該股票 “買入” 評級。22 位研究分析師對該股票給予了買入評級，4 位分析師對該股票給予了持有評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “適度買入”，平均目標價為 97.00 美元。</p>
</div><p><strong>View Our Latest Report on CVS</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CVS 的最新報告</strong></p>
</div><h2>Key Headlines Impacting CVS Health</h2>
<div class="lb-trans"><h2>影響 CVS Health 的關鍵頭條新聞</h2>
</div><p>Here are the key news stories impacting CVS Health this week:</p>
<div class="lb-trans"><p>以下是本週影響 CVS Health 的關鍵新聞故事：</p>
</div><ul>
<li>Positive Sentiment: JPMorgan raised its price target on CVS Health to $111 from $101 and kept an overweight rating, while Sanford C. Bernstein lifted its target to $106 from $94 and maintained outperform, signaling continued analyst confidence. Article Title</li>
<li>Positive Sentiment: CVS Health has been highlighted for strong Q1 results and improving profitability, with recent coverage noting the stock reached a new 52-week high after beating earnings and revenue expectations. Article Title</li>
<li>Positive Sentiment: Analysts and market commentary are also pointing to CVS as a top-ranked growth/dividend name, which may be helping sentiment around the stock. Article Title</li>
<li>Neutral Sentiment: CVS’s Omnicare subsidiary won bankruptcy court approval to sell its business to GenieRx, a step that should help CVS continue reshaping that unit, though it is more of a restructuring story than a direct earnings driver. Article Title</li>
<li>Neutral Sentiment: CVS also announced AI and MinuteClinic-related initiatives, including recognition for enterprise AI and a weight-loss program update, which support the company’s innovation narrative but are not likely immediate stock catalysts. Article Title</li>
<li>Negative Sentiment: There were no major fresh negative headlines in the latest batch; however, investors may still be watching execution risk around restructuring, formulary changes, and broader healthcare margin pressures.</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：摩根大通將 CVS Health 的目標股價從 101 美元上調至 111 美元，並維持超配評級，而桑福德·C·伯恩斯坦將目標從 94 美元上調至 106 美元，並維持跑贏大盤，顯示出分析師的持續信心。文章標題</li>
<li>積極情緒：CVS Health 因強勁的第一季度業績和改善的盈利能力而受到關注，最近的報道指出，該股票在超出盈利和收入預期後達到了新的 52 周高點。文章標題</li>
<li>積極情緒：分析師和市場評論也指出 CVS 是排名靠前的增長/分紅股票，這可能有助於提升對該股票的情緒。文章標題</li>
<li>中性情緒：CVS 的 Omnicare 子公司獲得破產法庭批准，將其業務出售給 GenieRx，這一步驟應有助於 CVS 繼續重塑該部門，儘管這更多是一個重組故事，而不是直接的盈利驅動因素。文章標題</li>
<li>中性情緒：CVS 還宣佈了與人工智能和 MinuteClinic 相關的舉措，包括企業人工智能的認可和減肥項目的更新，這些支持了公司的創新敍事，但不太可能成為立即的股票催化劑。文章標題</li>
<li>消極情緒：在最新一批中沒有出現重大新的消極頭條；然而，投資者可能仍在關注重組、處方變更和更廣泛的醫療保健利潤壓力的執行風險。</li>
</ul>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the business's stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares of the company's stock, valued at $907,714.14. The trade was a 87.28% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. 0.85% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 CVS Health 新聞中，執行副總裁 Tilak Mandadi 於 5 月 8 日星期五出售了 69,551 股公司的股票。股票以平均價格 89.58 美元出售，總價值為 6,230,378.58 美元。出售完成後，該執行副總裁直接持有 10,133 股公司股票，價值 907,714.14 美元。此次交易使其持股減少了 87.28%。該交易已在證券交易委員會的備案中披露，相關文件可通過此鏈接獲取。內部人士持有 0.85% 的股票。</p>
</div><h2>CVS Health Company Profile</h2>
<div class="lb-trans"><h2>CVS Health 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.</p>
<div class="lb-trans"><p>CVS Health Corporation 是一家多元化的醫療保健公司，運營着一個大型零售藥房網絡、藥房福利管理服務和醫療解決方案。公司總部位於羅德島州的伍恩索克特，追溯到 20 世紀 60 年代初，已發展成為處方藥、非處方產品、臨牀服務和健康保險產品的綜合提供商。其運營模式結合了零售藥房和店內診所與更廣泛的藥房和健康計劃能力。</p>
</div><p>Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.</p>
<div class="lb-trans"><p>主要業務活動包括 CVS 藥房零售業務、MinuteClinic 步入式醫療診所和提供擴展臨牀服務的 HealthHUB 地點。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than CVS Health</li>
<li>Oklo Stock Could Be Ready for Another Massive Run</li>
<li>D-Wave Earnings Looked Weak, But Investors May Be Missing This</li>
<li>Nebius Upside Expands as AI Feedback Loop Intensifies</li>
<li>Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 CVS Health</li>
<li>Oklo 股票可能準備再次大幅上漲</li>
<li>D-Wave 的財報看起來疲弱，但投資者可能忽視了這一點</li>
<li>隨着人工智能反饋循環的加劇，Nebius 的上行空間擴大</li>
<li>內部交易：Okta 和 Abbott 看到買入，Micron 內部人士出售</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CVS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 CVS 持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com，獲取 CVS Health Corporation（NYSE:CVS - 免費報告）的最新 13F 備案和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=CVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in CVS Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 CVS Health 嗎？</h2>
</div><p>Before you consider CVS Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 CVS Health 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 CVS Health 並不在名單上。</p>
</div><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CVS Health 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

World Investment Advisors Grows Position in CVS Health Corporation $CVS

Market Beat

巴克萊銀行

高盛

摩根大通

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

世界投資顧問公司擴大了在 CVS Health Corporation $CVS 的持倉